Arcturus Therapeutics Holdings Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $382.3M
- Price
- $13.45
- % Change (Daily % change from the live per-ticker quote feed.)
- +22.38%
- Volume
- 2.9M
About
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Quick stats
Shares outstanding28.4M
Computed float22.8M
Float / shares80.1%
Cash runway (months)31.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001768224
Websitehttps://arcturusrx.com
AI Summary
AI-generated1/27
majorbullishearnings
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus reported Q2 2026 revenue of $3.0 million, down from the prior year due to the wind-down of the CSL Seqirus collaboration, with a net loss of $23.8 million or $0.84 per share.
Pipeline progress remains on track with the ARCT-032 cystic fibrosis Phase 2 study expected to trigger a Phase 3 decision in Q4 2026, supported by a new strategic collaboration with Thermo Fisher for manufacturing and clinical services.
The company regained global rights to KOSTAIVE and its infectious disease portfolio, receiving $12 million in cash and the release of $16 million in liabilities, extending its cash runway to over two and a half years through the end of 2028.
Red flags
- Revenue declined to $3.0 million from $28.3 million in the prior year due to partnership termination
- Net loss widened to $23.8 million compared to $9.2 million year-over-year
- General and administrative expenses increased partly due to legal fees